- What approach to ALK-positive NSCLC?2020 | Faculty of Medicine in Pilsen, First Faculty of Medicine
- Optimal procedure in treatments of advanced ALK-positive and ROS1-positive non-small cell lung cancers2019 | Third Faculty of Medicine
- ROS1 - another potencional target of our patients2014 | Faculty of Medicine in Pilsen
- Two years longer and peaceful life thanks to alectinib2022 | Third Faculty of Medicine, Central Library of Charles University
- Advanced lung cancer as chronic disease2015 | Faculty of Medicine in Pilsen
- Targeted therapy of non-small cell lung cancer2021 | Faculty of Medicine in Pilsen
- Imunitně podmíněná pneumonitida u pacienta léčeného imunoterapií pro bronchogenní karcinom2019 | First Faculty of Medicine
